VCAR33ALLO is under clinical development by Vor BioPharma and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VCAR33ALLO’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VCAR33ALLO is under development for the treatment of post-transplantation refractory and relapsed acute myeloid leukemia. The therapeutic candidate comprises allogenic healthy donor-derived T-cells genetically modified to express chimeric antigen receptors (CAR) targeting cell expressing CD33. It is delivered through a lentivirus viral vector. It is administered by parenteral route.
Vor BioPharma overview
Vor BioPharma, a subsidiary of Puretech Health Plc, is a clinical-stage cell therapy company that develops therapies for the treatment of hematological malignancies. The company’s pipeline products include Trem-cel (formerly VOR33), is an eHSC product candidate created by genetically modifying healthy donor HSCs in order to remove the CD33 surface target protecting them from a targeted therapy post-transplant. Vor BioPharma‘s other pipelines include VCAR33 (Allogeneic), VCAR33 (Autologous), Trem-cel + VCAR33, Treatment System and CD33-CLL1 Treatment System. Vor BioPharma is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of VCAR33ALLO’s drug-specific PTSR and LoA scores, buy the report here.